UroGen Pharma Ltd. - Ordinary Shares (URGN) analyst actions
Rating and price-target actions on URGN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the URGN overview →
3 measured URGN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out | Press release | -1.18% | -1.77% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Stockholders to Reach Out | Press release | +1.64% | +5.62% | |
| UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102 | Press release | -1.27% | -4.51% |
Keep exploring
More URGN: earnings → · SEC filings → · URGN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.